Re: Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection. Am J Ther. 2022;29:e232.

Bryant, Andrew; Lawrie, Theresa A; Fordham, E.J.; Mitchell, Scott A.

doi:10.1097/mjt.0000000000001520

Cited by 3 publications

(3 citation statements)

References 18 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The conduct of this review was guided by a protocol that was initially written using Cochrane's rapid review template and subsequently expanded to a full protocol for a comprehensive review. 26…”

Section: Methodsmentioning

confidence: 99%

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Bryant

Lawrie

Dowswell

et al. 2021

American Journal of Therapeutics

176

106

View full text Add to dashboard Cite

Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion. Therapeutic Advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I 2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty. Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

show abstract

Section: Methodsmentioning

confidence: 99%

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Bryant

Lawrie

Dowswell

et al. 2021

American Journal of Therapeutics

176

106

View full text Add to dashboard Cite

show abstract

“…Using ivermectin at the start of an infection may help prevent it from progressing to a severe disease and has clearly shown a significant reduction in COVID-19 deaths. Because of its apparent safety and low cost, ivermectin is expected to have a considerable global impact on COVID-19 disease [13].…”

mentioning

confidence: 99%

Linear versus cubic regression models for analyzing generalized reverse degree based topological indices of certain latest corona treatment drug molecules

Arockiaraj¹,

Greeni

Kalaam

2023

Int J of Quantum Chemistry

View full text Add to dashboard Cite

The major challenges encountered by medical researchers in developing new drugs are time consumption, increased cost, establishing a safety profile for the drugs, poor solubility, and inadequate experimental data. In its theoretical aspects, chemical graph theory plays a vital role in drug design and development by analyzing the structural parameters of molecules. Topological indices aim at the mathematical representation of a molecular structure, which is used to analyze the effectiveness of drugs and enhance the drug development process. In this study, we consider certain recently used drugs such as dexamethasone, molnupiravir, nirmatrelvir, ivermectin, ribavirin, baricitinib, favipiravir, duvelisib, L‐ascorbic acid, sofosbuvir, remdesivir, and pioglitazone for omicron, delta and other variants of coronaviruses. For these drug molecules, we propose a generalized form of reverse degree parameters and compute their associated topological indices with limiting behaviors. We undertake QSPR study on the potential of generalized reverse‐degree indices using linear and cubic regression models.

show abstract

“…In 2021, the American Journal of Therapeutics hosted a vigorous debate regarding the quality of the primary data used by systematic reviewers to justify the therapeutic use of ivermectin for COVID-19. 5–11 We indicated at the time that the value of ivermectin for COVID-19 remained to be established by carefully designed and executed randomized, double-blinded, placebo-controlled trials. 12…”

mentioning

confidence: 99%

Ivermectin for COVID-19: The 2022 Update

Manu¹

2022

American Journal of Therapeutics

View full text Add to dashboard Cite

Re: Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection. Am J Ther. 2022;29:e232.

Abstract: FIGURE 3. Updated mortality analysis with exclusions of both Elgazzar and Niaee.

Cited by 3 publications

References 18 publications

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Linear versus cubic regression models for analyzing generalized reverse degree based topological indices of certain latest corona treatment drug molecules

Ivermectin for COVID-19: The 2022 Update

Contact Info

Product

Resources

About